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ABSTRACT
Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon 
cancer relapse indicates that a fraction of tumor cells survives treatment causing 
tumor recurrence. The majority of cancer cells divert metabolites into anabolic 
pathways through Warburg behavior giving an advantage in terms of tumor growth. 
Here, we report that treatment of colon cancer cell with 5-FU selects for cells with 
mesenchymal stem-like properties that undergo a metabolic reprogramming resulting 
in addiction to OXPHOS to meet energy demands. 5-FU treatment-resistant cells 
show a de novo expression of pyruvate kinase M1 (PKM1) and repression of PKM2, 
correlating with repression of the pentose phosphate pathway, decrease in NADPH 
level and in antioxidant defenses, promoting PKM2 oxidation and acquisition of stem-
like phenotype. Response to 5-FU in a xenotransplantation model of human colon 
cancer confirms activation of mitochondrial function. Combined treatment with 5-FU 
and a pharmacological inhibitor of OXPHOS abolished the spherogenic potential of 
colon cancer cells and diminished the expression of stem-like markers. These findings 
suggest that inhibition of OXPHOS in combination with 5-FU is a rational combination 
strategy to achieve durable treatment response in colon cancer.
INTRODUCTION
Colon cancer is one the most common tumors in 
western countries. Together with surgical intervention 
and radiotherapy, chemotherapy represents the first line 
of intervention to combat expansion of the tumor mass. 
Even with a promising initial response to pharmacological 
therapy, the majority of patients do not realize complete 
eradication of tumor cells, mainly due to selection of 
chemo-resistant cancer cells (CCCs). CCCs are a sub-
population of tumor cells refractory to conventional drugs 
or radiotherapy and highly prone to metastasize [1; 2] . For 
this reason, the presence of CCCs is often associated with a 
poor prognosis [3]. Indeed, overcoming chemo- resistance 
is one of the major challenges in oncology.
Despite an active and growing interest studying 
CCCs, the origin of CCCs and the phenotype that defines 
them remains strongly debated [4]. It has been suggested 
that CCCs could derive from cancer stem cells (CSCs), 
a non-differentiated subset of cancer cells isolated from 
several different tumors and characterized by an intrinsic 
resistance to apoptosis as well as by unusual phenotypic 
plasticity [5]. Some evidence suggests that drug-resistant 
stem-like cells could also originate from other cancer 
cells when environmental conditions become unfavorable 
[6]. According to this model, under stresses such as 
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hypoxia/anoxia, extreme acidity, nutrient deprivation, 
or contact with particular stromal cells, specific cancer 
cells can enter a slow proliferating/quiescent state, thus 
avoiding apoptosis [7–9]. When environmental conditions 
become permissive, these surviving cells re-differentiate, 
restarting to proliferate generating a heterogeneous tumor.
Several lines of evidence demonstrate that 
CCCs behave as CSCs, thus suggesting a common 
origin [10]. In fact most CCCs demonstrate a stem-like 
immunophenotype, self-renewal and tumor initiating 
capacity, as well as high motility and resistance to 
apoptosis. In addition, these cells have been shown to 
proliferate and regenerate new tumor masses in several 
mouse models [9]. These data suggest that CCCs 
resemble CSCs and are likely characterized by a peculiar 
metabolism, allowing them to survive stress conditions, 
and likely also contributing to their resistance to cytotoxic 
treatments.
Many highly proliferative cancer cells rely mainly 
on aerobic glycolysis (Warburg metabolism) for their 
energetics, which exploits carbons from glucose to 
produce ATP and other intermediates useful to sustain 
rapid growth [11; 12]. However, this metabolic strategy 
is not the most efficient to sustain a slow proliferating/
quiescent state [13]. Indeed, recent evidence supports 
the hypothesis that acquired resistance to therapy is 
accompanied by a metabolic shift toward respiratory 
metabolism [14; 15], suggesting that metabolic plasticity 
can have a role in survival of cells responsible for tumor 
relapse. For example, it has been observed that several 
drug-resistant tumor cells show a higher respiratory 
activity than parental cells [16–18]. In addition, different 
studies suggested that metformin, an inhibitor of complex I 
of electron transport chain, preferentially kills drug-
resistant cancer cells derived from different tumors, but 
has no effect on parental cells, reinforcing the hypothesis 
that acquisition of drug resistance may be accompanied 
by a shift toward oxidative metabolism [19–21]. 
Nevertheless, further validation of these data is required 
and represents an important starting point to develop new 
strategies to overcome chemo-resistance in cancer. Here 
we analyzed the functional and metabolic changes of 
colon cancer during the acquisition of chemoresistance to 
5-FU in vitro and in vivo.
RESULTS
5-FU resistance of HT29 colorectal cancer cells 
is associated with metabolic reprogramming 
toward OXPHOS
To decipher the metabolic changes associated 
with resistance to therapy in colorectal cancers, we used 
a model of HT29 human colon cancer cells resistant to 
5-FU (Suppl. Fig. 1A, 1B, 1C). The ability of selected 
cells to survive to treatment with 20 μM 5-FU was verified 
every week. We analyzed the metabolic profile of parental 
and 5-FU resistant cells before and after acute treatment 
with 20 μM 5-FU, excluding parental cells, which are 
95% dead after 72 h (Suppl. Fig. 1B). Acute treatment 
of 5-FU-resistant cells was associated with a strong 
decrease of glucose uptake and consumption (Fig. 1A and 
Suppl. Fig. 2A), as well as with a decrease of GLUT-1 
expression (Fig. 1B, and Suppl. Fig. 2B).
Extracellular flux analysis (Seahorse technology) 
showed that, under glucose deprivation, resistant cells 
significantly reduced lactate production, regardless of 
the presence of 5-FU in the growth medium. A 10 mM 
glucose pulse attenuated the difference in lactate 
production between sensitive and resistant cells: resistant 
cells continued to reproducibly produce less lactic 
acid compared to sensitive cells, but the difference was 
not statistically significant (Fig. 1C). Hovewer, direct 
quantification of released lactate reveals that 5-FU 
treated cells decrease production of lactate with respect to 
parental cells (Suppl. Fig. 2C). In addition, it is interesting 
to note that carbon dioxide production from (14C)glucose 
was higher in resistant cells treated with 5-FU compared 
to untreated and parental cells (Fig. 1D), suggesting that 
treatment with 5-FU increases the flux of glucose-derived 
carbons in the TCA cycle. Overall, these findings indicate 
that treated resistant cells reduce the glucose consumption 
and redirect pyruvate into the Krebs cycle instead of 
converting it into lactate.
Seahorse analysis further revealed that resistant cells 
have a significantly higher oxygen consumption rate, both 
under basal and carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP)-uncoupled conditions (Fig. 1E 
and Suppl. Fig. 2D). The oxygen consumption rate (OCR) 
analysis under treatment with oligomycin, an ATP-
synthase inhibitor, indicates an increased coupling between 
oxygen consumption and ATP production in resistant cells. 
Resistant cells maintain a spare respiratory capacity, which 
refers to their ability to upregulate OXPHOS for extra 
ATP under conditions of stress and/or increased energy 
demands [22; 23], similar to sensitive cells. All these 
characteristics suggest a higher mitochondrial activity in 
5-FU resistant cells upon exposure to the drug, further 
confirmed by direct measurement of the mitochondrial 
membrane potential using the TMRE dye (Fig. 1F). In 
keeping, we also confirmed an increase in mitochondrial 
mass in resistant cells in response to 5-FU (Suppl. Fig. 3A 
and 3B). Based on the recent indications of the role played 
by the SIRT1-PGC1-α axis in mitochondrial biogenesis 
correlated with chemoresistance [24], we confirmed the 
activation of this pathway also in our chemoresistant 
cells (Suppl. Fig. 3C). Analysis of NAD+/NADH ratio 
finally confirms the increased mitochondrial activity in 
chemoresistant cells upon treatment with 5-FU (Suppl. 
Fig. 3D).
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Figure 1: Chronic treatment with 20 μM 5-FU of HT29R decreases glucose utilization and commits cells to a 
respiratory metabolism. For HT29, HT29R and HT29R/5-FU cell cultures has been determined: A. glucose uptake measured using 
(U-14C)deoxy-D-Glucose; the amount of radiolabeled glucose incorporated by cells was determined using a liquid scintillator analyzer. 
Data were obtained normalized respect to cell number and reported as percentage respect to the control experiment. B. glucose transporter-1 
(GLUT1) expression levels determined by western blot analysis; the ratio between GLUT1 and Actin expression levels was reported in 
the box showed above the figure; C. extracellular acidification rates (ECAR) in the presence or not of glucose determined by XF analysis; 
D. 14CO2 production evaluated following incubation cancer cells with radiolabeled D-(U-14C)glucose; data were obtained normalized respect 
to cell number and reported as percentage respect to the control experiment E. Oxygen consumption rate (OCR) evaluated by XF analysis 
performed under mitochondrial stress conditions; F. mitochondrial membrane potentials evaluated through the TMRE Mitochondrial. 
Membrane Potential Assay Kit and a flow cytometry apparatus . Data reported in the graphics A, C, D, and E, represent the mean value 
+/− S.E.M. All experiments were carried out at least in triplicate. (**p < 0.01; *p < 0.05; #p > 0.1).
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Figure 2: Acute treatment with 20 μM 5-FU modifies redox equilibrium of HT29R cells inhibiting PPP and NADPH 
synthesis. For HT29, HT29R and HT29R/5-FU cell cultures has been determined: A. relative PPP rates, obtained measuring the differences 
between radiolabeled CO2 released after cells incubation with (6-
14C)glucose from the CO2 released from catabolism of (1-
14C)glucose. 
B. Relative NADPH levels determined through enzymatic assays. Each test was carried out in triplicate. Data reported in the figure represent 
the mean value +/− SEM. Data were normalized respect to protein content and reported as percent respect to the control experiment. 
C. Quantification of ROS levels carried out using DCFDA and flow cytometry, or D. measuring the fluorescence emitted from cells 
using a microplate fluorometer (Fluoroskan Ascent, ThermoFischer); E. expression levels of PKM1 and PKM2 evaluated by western blot; 
F. evaluation of redox status of PKM2 isoenzyme with BIAM. Data reported in the graphics A, B, and D, represent the mean value +/− 
S.E.M. All experiments were carried out at least in triplicate. (**p < 0.01; *p < 0.05; #p > 0.1).
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Figure 3: Chronic treatment with 20 μM 5-FU stimulates EMT in HT29R cells. A. Representative images of HT29, HT29R 
and HT29R/5-FU cells acquired through contrast phase microscopy. Scale bar 100 μm B. Immunoblot of the EMT keymarkers: E-Cadherin, 
N-Cadherin, β-catenin, Vimentin. C. Analysis of nuclear localization of β-catenin and Twist performed on purified nuclear fractions. D. In 
gel-MMP-2 and MMP-9 metalloproteinases activity. Migratory E. and invasive F. abilities of either HT29, HT29R or HT29R/5-FU cells 
determined using Boyden chamber assay. The data reported in the figures E and F, represent the mean value +/− S.E.M. All experiments, 
were carried out in triplicate. (**p < 0.01; *p < 0.05; #p > 0.1).
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To further validate our findings in another model, 
we established 5-FU resistant HCT116 colon cancer 
cells by prolonged culture in the presence of 20 μM 
5-FU. Acute treatment of 5-FU resistant cells decreased 
cell proliferation in the absence of cytotoxic effects. 
Conversely, parental HCT116 cells showed a robust 
apoptotic response analogous to that observed with 
the HT29 model (Suppl. Fig. 4A, 4B, 4C). Metabolic 
characterization of HCT116 parental and 5-FU resistant 
cells shows reduced glucose consumption in drug-
resistant cells (Suppl. Fig. 4D). Moreover, the decrease 
of glucose consumption was associated with increased 
OXPHOS activity (Suppl. Fig. 4E), as well as increased 
mitochondrial membrane potential (Suppl. Fig. 4F). 
To confirm in vivo resistance of HT29R cells to 5-FU, 
a xenograft model was established in mice and animals 
were randomized and treated with 10 mg/kg 5-FU. Results 
show robust antitumor activity of 5-FU in parental HT29 
cells, accompanied by a drastic reduction of proliferation 
and induction of apoptosis. Conversely, in HT29R-
derived tumors, 5-FU treatment only minimally reduced 
proliferation and did not induce apoptosis, indicating 
that HT29R cells retain their intrinsic resistance to 5-FU-
induced toxicity in vivo (Suppl. Fig. 5A, 5B, 5C).
5-FU treatment of HT29 resistant colorectal 
cancer cells causes oxidative stress 
associated with decreased pentose phosphate 
pathway (PPP)
Metabolic deregulation of cancer cells towards a 
Warburg behavior has been associated with increased 
glucose uptake, followed by accumulation of glycolytic 
intermediates and fueling PPP. Activation of PPP allows 
cancer cells to obtain ribose-5P and NADPH, key molecules 
to synthesize nucleotides and sustain the rapid growth of 
cancer cells, as well as to resist oxidative stress, a common 
feature of cancer cells undergoing therapeutic regimens. To 
understand if the down regulation of glycolytic pathways 
observed in 5-FU treated HT29R cells would also impact 
glucose flux through PPP, consequently increasing 
intracellular ROS levels, we evaluated the activity of PPP 
through C1/C6 (14C)glucose cell loading. We observed that 
5-FU treatment of HT29R cells caused a 90% reduction 
of PPP (Fig. 2A), accompanied by decreased NADPH 
accumulation and increased ROS production (Fig. 2B, 
2C, 2D and Suppl. Fig. 6A). OXPHOS is the major source 
of ROS production in cells; thus, increased oxidative 
stress can be a consequence of increased mitochondrial 
respiratory activity, as demonstrated by cytofluorimetric 
analysis and co-staining with Mitotraker and Mitosox 
(Suppl. Fig. 6B and 6C). Finally, because pyruvate kinase 
M2 (PKM2) isoenzyme is a key mediator of the Warburg 
effect and is responsible for diverting glucose into PPP 
to fuel protein synthesis and cell growth, we evaluated 
PKM2 expression in resistant cells. Interestingly, we 
observed that 5-FU treatment of HT29R cells leads to 
decreased expression of PKM2, accompanied by increased 
expression of the more active isoenzyme PKM1 (Fig. 2E 
and Suppl. Fig. 7A, and 7B). In addition, PKM2 expressed 
by 5-FU-treated cells was further inhibited through cysteine 
oxidation (Fig. 2F), in agreement with the oxidative stress 
sustained by PPP inhibition.
5-FU treatment of HT29R cells elicits epithelial-
mesenchymal transition and stemness phenotype
In order to correlate cancer cell malignancy to 
resistance to 5-FU treatment, we analyzed features 
that have been previously associated with metabolic 
deregulation of cells, including EMT and stemness. 
5-FU treatment of HT29R cells caused a spindle-like 
morphology (Fig. 3A) associated with enhanced EMT 
markers, such as decreased E-cadherin, increased 
N-cadherin and vimentin (Fig. 3B and Suppl. Fig. 8A, 
8B, 8C, 8D), and enhanced nuclear content of β-catenin 
and Twist transcription factor (Fig. 3C). In keeping with 
the engagement of an EMT program, 5-FU treatment 
of HT29R cells also caused a robust secretion of the 
metalloproteases (MMPs), MMP2 and MMP9 (Fig. 3D), 
key proteolytic enzymes driving mesenchymal motility. 
Consistent with secretion of MMPs, 3D motility as well as 
invasiveness through Matrigel barrier were both strongly 
activated by 5-FU treatment (Fig. 3E, 3F).
EMT has been associated in several cancer models 
with stem-like traits, such as expression of stemness 
markers, self-renewal capacity, and formation of 
anchorage-independent spheres. We observed that cells 
resistant to 5-FU had greatly enhanced the ability to form 
anchorage-independent spheres, and that maintenance 
of the stem-like phenotype, as well as the expression of 
the CD133 marker, was associated with 5-FU treatment 
(Fig. 4A, 4B, 4C). Indeed, analysis of spheres across 8 
passages indicated that chronic treatment of HT29R cells 
with 5-FU preserved the stem-like phenotype, whereas 
it is evident that untreated resistant cells gradually lose 
their ability to form colon spheres and CD133 expression 
(Fig. 4A, 4B, 4C). Even if the causes of this phenomenon 
remain to be clarified, it is likely that chemoresistant cells 
need the chronic administration of the drug to maintain 
stem-like traits that they have acquired. Taken together, 
these results indicate that acquisition of chemo-resistance 
does not correlate per se with a more motile and stem-like 
phenotype, but administration of 5-FU to resistant cells 
stimulates EMT and stem-like traits.
HT29R cells exposed to 5-FU are sensitive to 
inhibition of OXPHOS
To understand the role of metabolic reprogramming 
and activation of OXPHOS in 5-FU treated HT29 cells, 
we treated tumor cells in presence or absence of 5-FU 
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Figure 4: Analysis of stemness of HT29, HT29R and HT29R/5-FU cells. Resistant cells were treated for 72 h with 20 μM 5-FU 
and then assayed for their ability to form colon-spheres. A. contrast phase microscopy images of sphere obtained after 21 days (P1 generation). 
Scale Bar 200 μm. To evaluate their self-renewal ability, single spheres obtained in P1 generation were withdrawn, mechanically disrupted 
and then re-plated. The evaluation of colon-spheres forming ability of cancer cells, was carried out by counting the number of colon-spheres 
using a contrast phase microscopy. B. Quantification of colon spheres number at different passages. Data reported in the figures represent the 
mean values +/− S.E.M from at least three independent experiments. C. cytofluorimetric analysis of CD133+ positive cells in colon-spheres 
of different passages. Data reported in the figures represent the mean values +/− S.E.M from at least three independent experiments.
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Figure 5: Effect of 20 μM 5-FU and OXPHOS inhibitors treatment on cells viability. A. Calcein vital staining of cells 
growth in 3D; images of cells are obtained using a widefield automated microscope (ImageXpress® Micro XLS System); Scale Bar 
500 μm. B. Images of cancer cells, growth as spheres, acquired by contrast phase microscopy of HT29, treated for 3 days with or without 
5 mM meftormin, 500 nM Oligomycin, 1 μM Rotenone or 1 μM Antimycin; Scale Bar 100 μm. C. Quantification of apoptosis relative to 
doxorubicin treated cells obtained using Annexin V FITC apoptosis detection kit. D. Images, acquired by contrast phase microscopy of cells 
growth as spheres, and cultured for 48 h in presence of 5 mg/ml 2 DG; Scale Bar = 200 μm.
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Figure 6: Cell proliferation and cell cycle analysis of HT29, HT29R and HT29R/5-FU treated with metformin. A. Cell 
cycle analysis. After 72 hours, parental, resistant and resistant cells treated with 5-FU were fixed with ethanol and then stained with propidium 
iodide. Analyses of samples are carried out using a flow cytometry apparatus (FACSscan, BD Biosciences). Cell distribution between cell 
cycle phases was carried out using ModFit LT™ Highlights program. All test were carried out in triplicate. Data reported in the Table 
represent the mean values +/− S.E.M. Duplication time, was determined as described in Materials and Methods section. B. and C. Evaluation 
of HT29, HT29R and HT29R/5-FU cells growth rate in the absence (B) or presence (C) of 5 mM metformin. Number of cells is determined by 
cell counting using a contrast phase microscope. Values reported represent the mean value +/− S.E.M. All tests were carried out in triplicate.
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Figure 7: A. Analysis of PKM2, PKM1 and VDAC expression levels in samples derived from xenopatients. Representative 
H&E and immunofluorescence of patient derived xenografts untreated or treated with 5-FU. Images of samples were acquired using a 
fluorescence microscopy Nikon Eclipse. B. Scheme of metabolic profile of parental and resistant cells. The pictures highlight the metabolic 
profile of HT29 parental cells as well as the conversion of resistant cells from a glycolytic toward respiratory metabolism upon chronic 
treatment with 5-FU.
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with different OXPHOS inhibitors: Complex I inhibitors 
metformin and rotenone, Complex III inhibitor antimycin, 
or Complex V inhibitor oligomycin. Calcein staining 
showed that OXPHOS inhibition affected the ability 
of cells treated with 5-FU to grow in 3D conditions, 
but it did not impair clonogenity of either parental or 
untreated resistant cells (Fig. 5A, 5B). We also confirmed 
that HCT116 colon cancer cells resistant to 5-FU were 
addicted to respiratory metabolism (Suppl. Fig. 9A, 
9B). In addition, we observed that treatment with 
OXPHOS inhibitors strongly affected the viability of 
both HT29 and HCT116 resistant cells treated with 5-FU 
(Fig. 5C and Suppl. Fig. 9C). Administration of 5 mg/ml 
2-deoxyglucose, an inhibitor of Warburg-like behavior, 
for 48 h did not affect the spherogenic potential of 5-FU 
treated HT29R cells (Fig. 5D), thereby confirming that 
colon-spheres are likely addicted to OXPHOS to survive 
5-FU treatment.
To investigate the effect of combination treatment 
with 5-FU and metformin on cell growth and survival, we 
analyzed the effect of metformin on cell cycle and cell 
proliferation. The results indicate that 5-FU induces an 
elongation of cell cycle, which correlated with decreased 
proliferation of HT29R cells (Fig. 6A, 6B). Combined 
treatment with metformin and 5-FU induced death in the 
HT29R cells thereby confirming the complete addiction 
of these cells to OXPHOS. The requirement of OXPHOS 
for HT29R cells was also confirmed by treatment with 
electron transfer chain/OXPHOS inhibitors, as rotenone, 
antimycin A and oligomycin (Suppl. Fig. 10A, 10B, 10C, 
and 10D).
To validate our observations in vivo, we analyzed 
samples obtained from colon cancer xenotransplants 
using chemo-naïve stage III human colon adenocarcinoma 
treated weekly with 5-FU (50 mg/kg) and oxaliplatin 
(5 mg/kg) for their mitochondrial content and for PKM1/2 
expression. 5-FU-treated tumors expressed high levels of 
PKM1 and low levels of PKM2 compared to untreated 
tumors. In addition, 5-FU-treated tumors showed 
high levels of VDAC1 expression, a well-established 
mitochondrial protein marker, confirming that treatment 
with 5-FU increased mitochondrial content in resistant 
cells in vivo (Fig. 7).
DISCUSSION
Data reported herein indicate that under chronic 
treatment with 5-FU, i) colon cancer cells resistant to 
5-FU plastically shift their metabolism towards OXPHOS; 
ii) revert their addiction to a Warburg-like metabolism by 
inverting the ratio between PKM2 and PKM1 glycolytic 
enzymes; iii) this metabolic adaptation is related to the 
commitment of cancer cells to EMT, increased motility 
and achievement of stem-like traits; iv) OXPHOS 
inhibition, in combination with 5-FU, dramatically 
affects survival of resistant cells. All these effects are not 
observed or dramatically attenuated in untreated resistant 
cells.
Expression of PKM2 in tumor and proliferating cells 
sustains Warburg metabolism. The inversion of the ratio 
between PKM1 and PKM2 in favor to the latter, as well as 
tyrosine phosphorylation or cysteine oxidation of PKM2, 
have been correlated with high cellular proliferation. 
Our data indicate that in resistant cells, the continued 
administration of 5-FU leads to increased expression of 
PKM1 and decreased expression of PKM2. Moreover, 
PKM2 activity is also inhibited by cysteine oxidation.
Consistent with the reversal of the PKM2/PKM1 
ratio, 5-FU-treatment resistant cells showed a higher 
respiratory capacity compared to parental cells but also a 
surprising metabolic plasticity. Indeed, the shift towards 
OXPHOS was strongly attenuated upon removal of the 
drug, rescuing a Warburg-like phenotype. In keeping 
with the advantage given by Warburg metabolism in 
terms of accumulation of glycolytic intermediates, the 
proliferation rate of resistant cells is similar to that of 
parental cells in the absence of 5-FU, and these cells rely 
on glycolytic pathway to satisfy their metabolic needs. 
Conversely, 5-FU-treated resistant cells strongly decrease 
their proliferation rate and shift toward OXPHOS. Data 
obtained from patient-derived xenograft mouse models 
confirmed that treatment with 5-FU correlated with 
decreased PKM2 and increased PKM1 expression, as 
well as with increased mitochondrial mass (VDAC1), thus 
validating data obtained in vitro.
Notably, 5-FU-treated resistant cells show elevated 
levels of ROS in response to drug administration and a 
decrease in NADPH levels, consistent with the robust 
decrease in PPP in 5-FU treated resistant cells. This finding 
is in apparent contradiction with the metabolic behavior 
of these cells. Indeed, Warburg metabolism has been 
correlated with accumulation of glycolytic intermediates 
due to the expression of the rate-limiting PKM2, thereby 
shunting glucose into PPP to obtain pentoses for nucleic 
acids synthesis, anabolism and proliferation. In addition, 
up-regulation of PPP is a consolidated mechanism 
exploited by several cancer cells to control intracellular 
ROS levels, thereby protecting themselves from oxidative 
stress and death [25]. We argue that in 5-FU-treated 
resistant cells the reduction of glycolytic flux is the main 
inhibitor of PPP, which results in the observed decrease 
in NADPH synthesis and increase of ROS that are mainly 
produced by leaking electrons from the electron transport 
chain. Nevertheless, we cannot exclude that the limited 
NADPH availability could per se prevent the regeneration 
of antioxidants, thereby contributing to elevate ROS 
levels in 5-FU resistant treated cells. We explain these 
findings with the low proliferation rate of 5-FU treated 
resistant cells, which likely do not need to fuel anabolic 
pathways starting from PPP (nucleic acid synthesis) 
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or from glycolytic (aminoacids) intermediates, at least 
as highly proliferating cells. This metabolic adaptation 
allows OXPHOS-addicted cancer cells to easily survive 
drug treatments, but leaves cells susceptible to inhibitors 
of OXPHOS.
In the last decades, several studies demonstrated that 
deregulation or mutations of several metabolism-related 
enzymes are common features of cancer cells, with the 
consequence that most of these rely on aerobic glycolysis 
to satisfy their metabolic needs. These features renew 
hope that targeting cancer cell metabolism may improve 
patient survival [26–28]. As tumors are heterogeneous 
systems in which highly proliferative cells coexist with 
subpopulations of quiescent or slowly proliferating 
cells, i. e. cancer stem cells or tumor-initiating cells, the 
disparate metabolic phenotypes of tumor subpopulations 
have attracted the interests of molecular oncologists. CCCs 
show a puzzled metabolic behavior, mainly due to their 
unusual plasticity [29; 30]. Some preliminary indications 
suggest that these cells, endowed with self-renewal 
and stem-like traits, exploit mitochondrial respiration 
to survive and support their low rate of proliferation, 
although this indication is usually indirect [31]. Indeed, 
several papers address the efficacy of metformin in 
eradicating cancer stem cells [32–34]. Metformin is an 
approved antidiabetic drug that inhibits mitochondrial 
respiration by blocking complex I of the electron transport 
chain. Compelling evidence demonstrates that metformin 
shows a preferential cytotoxic activity toward cancer stem 
cells, thus preventing tumor relapse [21]. The general 
interest of oncologists around metformin is justified by its 
success in recent clinical trials in some aggressive cancers 
[35–38], as well as by recent indications of its synthetic 
lethality in association with chemotherapy drugs [39–
44]. We report here that metformin is active in de novo 
sensitizing resistant cells to 5-FU treatment. We argue 
that metformin mainly targets OXPHOS-addicted cells, 
as the effects of metformin treatment were phenocopied 
by others OXPHOS inhibitors. Indeed, all these molecules 
fully abrogated survival to 5-FU-resistant cells, as well 
as motility and achievement stem-like traits, strongly 
supporting the synthetic lethality of OXPHOS-inhibitors 
for 5-FU treatment-resistant cells.
Although we lack a mechanistic explanation of the 
shift towards OXPHOS of 5-FU-treated resistant colon 
cancer cells, we hypothesize that it is the result of adaptive 
metabolic reprogramming. Recent data indicate that 5-FU 
leads to activation of ataxia-telangiectasia mutated serine/
threonine protein kinase (ATM), AMP kinase (AMPK) and 
PGC-1α, which could promote mitochondrial biogenesis 
and stimulate OXPHOS [45–47]. Our results indicate that 
metformin, which has been reported to inhibit complex I in 
OXPHOS, is almost completely ineffective against colon 
cancer cells in the absence of 5-FU. 5-FU administration 
is mandatory to achieve the metabolic reprogramming 
of cancer cells to OXPHOS, thereby increasing their 
sensitivity to metformin. This observation indicates that 
OXPHOS inhibition is the primary mechanism of action of 
metformin resulting in anti-tumor effects, while targeting 
AMPK plays a marginal role. Moreover, the metabolic 
shift towards OXPHOS is completely reversible once 
5-FU is removed, confirming that metformin loses its 
effect when used alone.
Our observation that drug sensitivity and 
achievement of stem-like features correlate with a 
reliance on OXPHOS in colon cancer cells is in line with 
very recent work indicating OXPHOS as mandatory for 
cancer malignancy. First, oncogene ablation in a model 
of pancreatic cancer resulted in rapid tumor regression 
but favored the selection of a subpopulation of cancer 
cells with stem-like properties that relies on OXPHOS 
for survival and were responsible for tumor relapse 
[18]. Second, it has been reported that that expression 
of PGC-1α, a transcriptional coactivator that stimulate 
mitochondrial biogenesis and OXPHOS, increases cancer 
cell invasiveness and correlates with survival of circulating 
cancer cells, as well as their metastatic dissemination, 
suggesting that mitochondrial activity contributes to the 
development of resistant and malignant cancer phenotypes 
[48]. SIRT1/PGC1-α axis has also been correlated with 
chemoresistance and metabolic shift towards OXPHOS 
in liver metastasis of colon cancer [24]. Moreover, 
Porporato recently associated high mitochondrial activity 
of melanoma cells with a hypermetastatic phenotype [49]. 
Last, glioblastoma cells resistant to temozolomide showed 
a prevalent respiratory metabolism [16]. Altogether, these 
findings suggest that new therapeutic strategies that 
incorporate targeting of OXPHOS may selectively kill 
CCCs and yield more durable responses.
MATERIALS AND METHODS
Materials, cell lines and assays
HT29 colon carcinoma cells were kindly provided by 
M. Landriscina (University of Foggia) and authenticated 
by PCR/short tandem repeat analysis. HT29 resistant to 
5-FU (HT29R) were selected as previously reported [50]. 
To ensure maintenance of resistance to 5-FU, HT29R cells 
were steadily grown in the presence of with 20 μM 5-FU. 
HCT116 were purchased from American Collection of 
Cell Cultures (ATCC). For 3D tissue culture, cells were 
maintained in low-attachment plates in media composed 
of 2% methylcellulose in Mammary Epithelial Basal 
Medium (Lonza) supplemented with 5 mM Glutamine, 
10 μg/ml EGF, 10 μg/ml FGF, and 1X B27 Serum Free 
Supplement.
Unless specified, all reagents were from Sigma and all 
the antibodies were from Santa Cruz Biotechnology, except 
for the following: anti-PKM1, anti-PKM2 (Cell Signaling 
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Technology), anti-CD133 (Miltenyi), anti β-catenin 
(BD Biosciences). Intracellular production of ROS was 
assayed by Cell ROX (Life Technologies) or H2DCF-DA 
as previously described [51]. Immunoprecipitation and 
immunoblots were performed as previously described [52].
Glucose concentration in the medium was measured 
using a Glucose Assay Kit (Sigma-Aldrich) and NADPH 
content using an NADP/NADPH Assay Kit (AbCam).
Statistical analysis of data
Analysis of proteins expression levels, the MTT 
assays for determination of the IC50 values against 5-FU, 
tests for quantification of CO2, ROS, enzymatic assays 
for determination of cellular NADPH and NADH levels, 
the assays of glucose uptake, the colon sphere forming 
ability assays, the tests for the quantification of CD133+ 
expression, the assays for evaluation of cellular growth rate, 
the assays for the quantification of percentage of apoptotic 
cells, as well as the in vivo experiments were carried out at 
least in triplicate. Results are expressed as means ± S.E. M. 
and were analysed using the Student’s t test. A p value < 
0.05 was considered statistically significant.
Apoptosis evaluation
Apoptosis was determined using Annexin V and 
Dead Cells Assay from Merck Millipore according to 
manufacturer’s instructions. Cells were analyzed by 
flow cytometry. To determine viability of cells grown in 
3D conditions, cells embedded in methylcellulose-based 
semisolid media were incubated for 30 minutes with 1 μM 
calcein (Life Technology) and quantified through ImageX 
press velos (Molecular Devices) apparatus.
Colony formation assay
For colony formation assays, 500 cells were seeded 
into a six-well plate, treated for 3 days with 5-FU 20 μM, 
Oligomycin 500 nM, Metformin 5 mM, Rotenone 1 μM, 
or Antimycin 1 μM. The medium was replaced and cells 
were cultured for 9–11 days. Subsequently, cells were 
fixed and stained with a solution containing 1% crystal 
violet (Sigma–Aldrich), and 10% methanol. Colonies 
were photographed and counted using a GelDoc imaging 
system (Bio-Rad Laboratories).
Cell migration in Boyden Chamber
Cell migration was performed with 5 × 104 HT29 
and HT29R/5-FU cells on 8-μm-pore Transwells (Corning) 
for 24 h, as previously described [51]. Chemotaxis was 
evaluated by counting the cells migrated to the lower 
surface of the filters (six randomly chosen fields). To 
evaluate cell invasiveness, Transwells were coated with 
50 μg/cm2 of reconstituted Matrigel.
Flow cytometry analysis
Cell cycle analysis was carried out using 
cytofluorimetric method. Briefly, HT29 and resistant 
cells were grown for 72 hours and then cells were fixed 
in 70% cold ethanol. After cells were re-suspended in a 
buffer containing 0.05 mg/ml propidium iodide, 5 μg/ml 
RNAase A, 0.2% v/v Nonidet P-40, 0.1% sodium citrate. 
Samples were analyzed by FACSscan flow cytometer 
apparatus (BD Biosciences). Doubling time was 
extrapolated using the following formula: Td = 24*lg2/
(lg(n°cell*t1)-(n°cell*t0)). To evaluate mitochondrial 
membrane potential, cells were stained with 500 nM 
Tetramethylrhodamine, ethyl ester (TMRE) dye for 
20 min at 37°C and flow cytometry was performed using 
a FACSscan (BD Biosciences). To evaluate the fraction 
of CD133 positive cells, 1 × 106 HT29, HT29R and 
HT29R/5-FU cancer cells were labelled with FITC- anti-
CD133 (human clone: AC133) antibodies for 1 h at 4°C 
in the dark. Then, cells were washed and analysed by flow 
cytometry using a FACSscan (BD Biosciences).
Glucose uptake
One hundred thousands HT29 or HT29/5-FU cells 
were cultured for 72 h. Cells were incubated for 15 min at 
37°C in a buffer solution (140 mmol/L NaCl, 20 mmol/L 
Hepes/Na, 2.5 mmol/L MgSO4, 1 mmol/L CaCl2, and 
5 mmol/L KCl, pH7.4) containing 0.5 μCi/mL (U-14C)
deoxy-D-Glucose (PerkinElmer). Cells were lysed in 
0.1 mol/L NaOH and assayed to determine the amount 
of (U-14C)deoxy-D-Glucose incorporated using a liquid 
scintillation analyzer (Tri-Carb 2800TR, PerkinElmer).
Detection of released CO2 by radioactive glucose
One hundred thousands HT29 cells treated or not 
with 5-FU were cultured for 72 h and then 0.2 μCi/mL 
D-(U-14C)glucose was added for 15 min at 37°C. 
Each plate had a taped piece of Whatman paper facing 
the inside of the dish wetted with 100 μL of phenyl-
ethylamine-methanol (1:1) to trap CO2. Then, 200 μL of 
4M H2SO4 was added to cells and incubated at 37°C for 
1 h to permit release of 14CO2. Finally, Whatman paper 
was removed and transferred to scintillation vials for 
counting. The amount of 14CO2 trapped on the paper dishes 
was determined using a liquid scintillator analyzer (Tri-
Carb 2800TR, PerkinElmer)
Extracellular Flux (XF) analysis (Seahorse 
technology)
The Oxygen Consumption Rate (OCR, pmolesO2 
consumed/min) and the ExtraCellular Acidification Rate 
(ECAR, mpH/min) were determined by using the XF24 
Extracellular Flux Analyzer (Seahorse Bioscience) 
according to manufacture’s instructions. Cells were plated 
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at 5 × 104 cells/well on XF24-well microplates in standard 
medium. After one day incubation, before were washed 
three times with an unbuffered assay medium (pH = 7.4) 
and conditioned for 1 h at 37°C without CO2 and assayed. 
After XF measurements, protein content from each well 
was determined by using Bradford assay.
PPP analysis
One hundred thousands HT29 cells treated or not 
with 5-FU were cultured for 72 h, serum starved and 
incubated with 0.5 μCi/ml D-(1-14C(U))glucose and 
0.5 μCi/ml D-(6-14C(U))glucose (PerkinElmer) for 1 h at 
37°C. The extent of PPP metabolic flux was obtained by 
subtracting the CO2 developed from (6-
14C)glucose from 
the CO2 released from (1-
14C)glucose.
MMP zymography
Culture media was loaded on 8% SDS-PAGE gels 
copolymerized with 0.1% (w/v) type A gelatin. Gels were 
incubated in 50 mmol/L Tris-HCl (pH 7.4), 200 mmol/L 
NaCl, and 5 mmol/L CaCl2 at 37°C for 24 hours, stained 
with 0.1% Comassie blue in acetic acid, methanol and 
distilled water (1:2:3). Destained gels were scanned with 
Quantity-One Image Analysis software (Bio-Rad).
Detection of PKM2 oxidation by 
carboxymethylation
One million HT29 cells were lysed for 15 min with 
oxygen-free lysis buffer containing 100 μM N-(biotinoyl)-
N0-(iodoacetyl) ethylenediamine (BIAM; Molecular 
Probes). After clarification, PKM2 was immunoprecipitated 
from 500 μg of total protein and redox state was revealed 
by HRP-conjugated streptavidin (Pierce).
Immunofluorescence analysis
Formalin-fixed tumors were dehydrated and paraffin 
embedded according to standard procedures. 5-μm slices 
were cut using a microtome, rehydrated, and subjected 
to antigen unmasking by heating at 95 °C for 30 minutes 
with a commercially available antigen unmasking solution 
(Citra). Samples were incubated with primary antibodies, 
washed, and incubated with fluorescent labelled secondary 
antibodies. Nuclei were stained through 4′,6-diamidin-2-
fenilindolo (DAPI) incubation and slices were mounted. 
Immages of samples were acquired using a fluorescence 
microscopy Nikon Eclipse Ni, equipped with a digital 
camera (Hamamatsu Digital Camera C11440).
Colon sphere assay
One thousand HT29 cells were plated in stem cell 
medium (SCM) MEBM (Lonza) supplemented with 
2 mM glutamine (Invitrogen), B27 (Invitrogen), 20 ng/ml 
hEGF (PeproTech), 20 ng/ml hFGF (PeproTech), 5 μg/ml 
Insulin (Roche), 0.5 μM hydrocortisone (Sigma), 100 μM 
β-mercaptoethanol (Sigma), 4 μg/ml heparin (Sigma). 
Methocult M3134 (StemCell Technologies) was added 
to SCM (final concentration 0.8%) to keep tumour cells 
growing as clonal spheres. After 7 days cultured tumour 
spheres were collected, digested with 0.05% trypsin 
(Gibco) to single cells and re-plated in culture.
Establishment of xenografts from human tumors
Excess tumor tissues not needed for clinical 
diagnosis from colorectal cancer resection specimens 
were cut into 2- to 3-mm3 pieces in antibiotic-containing 
Roswell Park Memorial Institute (RPMI) medium. Pieces 
of non-necrotic tissue were selected and immersed in 
Matrigel. Under anesthesia with isofluorane, tumors were 
implanted into 5- to 6-week-old female Nu+/Nu+ mice 
through a small incision creating a subcutaneous pocket 
in each side of the lower back (one tumor fragment per 
pocket). Tumors were harvested and stored for biological 
assays when they reached 1,500 mm3 in diameter. This 
set of xenografts were called F1. Additional xenograft 
generations were obtained for subsequent expansion and 
drug treatment. The research protocol was approved by 
the MD Anderson Cancer Center Institutional Review 
Board and informed consent was collected from all 
patients enrolled in the patient xenograft study protocol. 
The research protocol was also approved by the MDACC 
Animal Use and Care Committee and animals were 
maintained in accordance to guidelines of the American 
Association of Laboratory Animal Care. Xenografts from 
subsequent mouse-to-mouse passage were allowed to 
grow to a size of 200 (or 150–300) mm3. 5-FU (50 mg/kg) 
was administered as a weekly intraperitoneal injection. 
Mice were sacrificed after 18 days of treatment.
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